FDA Approves Gazyva to Reduce Relapse Risk in Patients With Idiopathic Nephrotic Syndrome by Chad Birt| Published on: Oct 26, 2026

FDA Approves Gazyva to Reduce Relapse Risk in Patients With Idiopathic Nephrotic Syndrome by Chad Birt| Published on: Oct 26, 2026 Andrea Callaway, president and founder of The Nephrotic Syndrome Foundation, discusses the FDA approval of Gazyva (obinutuzumab) for idiopathic nephrotic syndrome (INS) and what the approval means for affected families. https://checkrare.com/fda-approves-gazyva-to-reduce-relapse-risk-in-patients-with-idiopathic-nephrotic-syndrome/